Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.57 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3846689 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPK1KMT2AMEN1HCRTR1 | |
| SCHEMBL13606613 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPK1KMT2AMEN1HCRTR1 | |
| SCHEMBL1921333 | 0.91 | NPC1 (0.62) | SMN1; SMN2MAPK1KMT2AMEN1HCRTR1 | |
| SCHEMBL13606614 | 0.91 | NPC1 (0.62) | SMN1; SMN2MAPK1KMT2AMEN1HCRTR1 | |
| SCHEMBL1921332 | 0.91 | NPC1 (0.62) | SMN1; SMN2MAPK1KMT2AMEN1HCRTR1 | |
| SCHEMBL7976134 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPK1KMT2AMEN1HCRTR1 | |
| SCHEMBL7990269 | 0.81 | MAPK1 (0.53) | SMN1; SMN2MAPK1KMT2AMEN1HCRTR1 | |
| SCHEMBL7990128 | 0.80 | MAPK1 (0.57) | SMN1; SMN2MAPK1KMT2AMEN1HCRTR1 | |
| SCHEMBL7986305 | 0.80 | MAPK1 (0.56) | SMN1; SMN2MAPK1KMT2AMEN1HCRTR1 | |
| SCHEMBL7986343 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPK1KMT2AMEN1HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036560-A1 | (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione for the treatment of benign prostatic hypertrophy | ICOS Corporation (US) | 2009-03-18 | — | — | EP | disclosed |
| US-6784179-B2 | treating a vascular disease by administering e.g. tadalafil in combination with an endothelium-derived relaxing factor, an atrial natriuretic factor, a brain natriuretic peptide, a C-type natriuretic peptide, or an endothelium-dependent relaxing agent such as serotonin | ICOS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | ICOS CORPORATION | 2002-08-29 | — | — | US | disclosed |
| US-6369059-B1 | INHIBITOR OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP SPECIFIC PDE); CARDIOVASCULAR DISORDERS; PYRAZINO(2',1':6,1)PYRIDO(3,4-B)INDOLE-1,4-DIONES | ICOS CORPORATION | 2002-04-09 | — | — | US | disclosed |
| EP-0828479-B1 | METHOD OF PRODUCING A SOLID DISPERSION OF A POORLY WATER SOLUBLE DRUG | ICOS CORP (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1113800-A1 | COMBINATIONS OF TETRACYCLIC CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS WITH FURTHER THERAPEUTIC AGENTS | ICOS CORPORATION (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015228-A1 | COMBINATIONS OF TETRACYCLIC CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS WITH FURTHER THERAPEUTIC AGENTS | ICOS CORPORATION (US) | 2000-03-23 | — | — | WO | disclosed |
| EP-0740668-B1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | ICOS CORP (US) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | PDE3A, PDE3B, PDE2A | SMN1; SMN2 2998/4885MAPK1 452/4885KMT2A 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.